A detailed history of Portside Wealth Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Portside Wealth Group, LLC holds 18,052 shares of ABBV stock, worth $4.22 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
18,052
Previous 18,006 0.26%
Holding current value
$4.22 Million
Previous $3.34 Billion 25.05%
% of portfolio
0.58%
Previous 0.5%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

BUY
$184.85 - $231.54 $8,503 - $10,650
46 Added 0.26%
18,052 $4.18 Billion
Q2 2025

Aug 11, 2025

SELL
$170.16 - $206.27 $19,228 - $23,308
-113 Reduced 0.62%
18,006 $3.34 Billion
Q1 2025

Apr 14, 2025

BUY
$169.2 - $216.66 $503,031 - $644,130
2,973 Added 19.63%
18,119 $3.8 Billion
Q1 2025

Apr 10, 2025

BUY
$169.2 - $216.66 $188,996 - $242,009
1,117 Added 7.95%
15,159 $2.69 Billion
Q4 2024

Apr 14, 2025

SELL
$164.99 - $203.87 $2,144 - $2,650
-13 Reduced 0.09%
15,146 $2.69 Billion
Q4 2024

Jan 15, 2025

SELL
$164.99 - $203.87 $134,466 - $166,154
-815 Reduced 5.49%
14,042 $2.77 Billion
Q3 2024

Oct 31, 2024

BUY
$163.84 - $199.33 $13,271 - $16,145
81 Added 0.55%
14,857 $2.93 Billion
Q2 2024

Jul 18, 2024

SELL
$154.79 - $180.76 $76,930 - $89,837
-497 Reduced 3.25%
14,776 $2.53 Billion
Q1 2024

Apr 17, 2024

SELL
$159.82 - $182.1 $245,962 - $280,251
-1,539 Reduced 9.15%
15,273 $2.78 Billion
Q4 2023

Jan 16, 2024

SELL
$137.6 - $154.97 $79,257 - $89,262
-576 Reduced 3.31%
16,812 $2.61 Billion
Q3 2023

Oct 27, 2023

BUY
$133.59 - $154.65 $78,016 - $90,315
584 Added 3.48%
17,388 $2.59 Billion
Q2 2023

Sep 01, 2023

SELL
$132.51 - $164.9 $89.1 Million - $111 Million
-672,160 Reduced 97.56%
16,804 $2.26 Billion
Q2 2023

Aug 01, 2023

BUY
$132.51 - $164.9 $91.3 Million - $114 Million
688,964 New
688,964 $92.8 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Portside Wealth Group, LLC Portfolio

Follow Portside Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Portside Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Portside Wealth Group, LLC with notifications on news.